US STOCK
VRTX Stock Analysis
US stocks · market data · technical indicators
Vertex Pharmaceuticals Incorporated
VRTXUS stocksQuote delayed 15 min
9/11 下午01:32 updated
$514.56
-6.56-1.26%
Open
$519.13
High
$522.60
Low
$514.32
Volume
81.59萬
VRTX price history
-0.36%Open
516.44
Latest
514.56
High
557.96
Low
505.75
Average
538.04
Advertisement
AI Composite Technical Analysis
BetaFormula: fundamentals (40%) + technical indicators (30%) + market sentiment (30%)
AI Score60
Score range 0–100; a higher score indicates a stronger buy signal
Market Status
HoldCurrent Price$514.56
Target Price$566.016
Change %-1.26%
Institutional
Net Buying
Foreign Ownership
Reducing
Market Heat
Cautious
Fundamentals (US)
P/E Ratio
30.06x
ROE
23.54%
P/B Ratio
6.47x
Dividend Yield
--
Market Insight
The score sits in neutral territory (60/100). Waiting for a clearer signal may be warranted. Return on equity of 23.54% indicates solid profitability. The target price implies roughly 10.00% upside.
This analysis is for reference only and does not constitute investment advice. Investing carries risk; educational content only.
Financial snapshot
VRTX - Vertex Pharmaceuticals Incorporated
EPS
17.19USD
Forward EPS
20.13USD
P/E
30.06x
Forward P/E
25.67x
P/B
6.47x
ROE
23.54%
ROA
11.93%
Operating margin
38.06%
Profit margin
35.00%
Revenue growth
12.50%
Earnings growth
8.00%
Dividend yield
--
Financial statements
| 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | |
|---|---|---|---|---|---|
| Revenue | $3.33B | $2.99B | $3.19B | $3.08B | $2.96B |
| Gross profit | $2.84B | $2.59B | $2.72B | $2.66B | $2.56B |
| Operating income | $1.27B | $1.14B | $1.13B | $1.24B | $1.15B |
| Net income | $1.10B | $1.03B | $1.19B | $1.08B | $1.03B |
| Basic EPS | 4.34 | 4.06 | 4.69 | 4.24 | 4.02 |
| Diluted EPS | 4.31 | 4.02 | 4.65 | 4.20 | 3.99 |
Estimates vs actuals
Next earnings
2026-11-02
EPS estimate
-2.35
Revenue estimate
$3.42B
Last surprise
-0.32%
| Date | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-11-02 | -2.35 | Not reported | — |
| 2026-08-03 | 4.75 | 4.73 | -0.32% |
| 2026-05-04 | 4.31 | 4.47 | +3.81% |
| 2026-02-12 | 5.15 | 5.03 | -2.30% |
| 2025-11-03 | 4.58 | 4.80 | +4.87% |
| 2025-08-04 | 4.25 | 4.52 | +6.33% |
| 2025-05-05 | 4.29 | 4.06 | -5.44% |
| 2025-02-10 | 4.02 | 3.98 | -1.00% |
| 2024-11-04 | 4.13 | 4.38 | +5.96% |
| 2024-08-01 | -11.75 | -12.83 | -9.17% |
| 2024-05-06 | 4.06 | 4.76 | +17.28% |
| 2024-02-05 | 4.09 | 4.20 | +2.78% |
Institutional holders
| Institution | Quarter | Value held | Portfolio weight |
|---|---|---|---|
| VANGUARD GROUP INC | 2025-12-31 | $10.9B | 0.16% |
| BlackRock Inc. | 2024-06-30 | $10B | 0.23% |
| STATE STREET CORP | 2026-06-30 | $5.9B | 0.17% |
| CITADEL ADVISORS LLC | 2026-06-30 | $253.5M | 0.03% |
| RENAISSANCE TECHNOLOGIES LLC | 2026-06-30 | $159M | 0.22% |
| TWO SIGMA INVESTMENTS, LP | 2026-06-30 | $141.6M | 0.10% |
| Bridgewater Associates, LP | 2026-06-30 | $5.4M | 0.02% |
13F quarterly filings. Reporting periods differ by institution; value and weight reflect each institution's own latest quarter.
Analyst ratings
Mean target
$569.19
Target range
$350.00 – $672.00
Implied upside
10.14%
Strong buy
6
Buy
19
Hold
4
Sell
1
Strong sell
1
Advertisement